In addition to reducing the activation of the CXCL1-CXCR2 axis in tumors, this axis can be used as part of anti-cancer therapy using the conjugation of daunorubicin with CXCL1 [63], where CXCL1 serves as a transporter for daunorubicin (Table 1). The gene discussed is CXCR2; the disease is cancer.